scholarly article | Q13442814 |
P50 | author | Andreas Dötsch | Q38318250 |
Susanne Häussler | Q42673764 | ||
Iris Chaberny | Q42801671 | ||
Sebastian Bruchmann | Q57191622 | ||
P2093 | author name string | Bianka Nouri | |
P2860 | cites work | DNA gyrase, topoisomerase IV, and the 4-quinolones | Q24643546 |
Site-directed mutagenesis by overlap extension using the polymerase chain reaction | Q27860503 | ||
Primer3 on the WWW for general users and for biologist programmers | Q27861030 | ||
Selection of resistant bacteria at very low antibiotic concentrations | Q28479239 | ||
A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants | Q29547327 | ||
High throughput automated allele frequency estimation by pyrosequencing | Q33352030 | ||
Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility | Q33372694 | ||
Genomewide identification of genetic determinants of antimicrobial drug resistance in Pseudomonas aeruginosa | Q33424246 | ||
Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. | Q33975861 | ||
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. | Q33976675 | ||
Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates | Q33981394 | ||
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance | Q33982709 | ||
Mechanism of plasmid-mediated quinolone resistance | Q34025874 | ||
The worldwide emergence of plasmid-mediated quinolone resistance | Q34569740 | ||
Fluoroquinolone antimicrobial agents | Q34613302 | ||
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances | Q34750112 | ||
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study | Q34932869 | ||
Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. | Q35107937 | ||
Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem | Q35119495 | ||
The mutant selection window and antimicrobial resistance | Q35153856 | ||
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro | Q35821472 | ||
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli | Q35879095 | ||
Efflux-mediated antimicrobial resistance | Q36138147 | ||
Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options | Q36268383 | ||
Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation | Q36295397 | ||
Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa | Q37348842 | ||
Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit | Q37401036 | ||
Quinolones: action and resistance updated | Q37595559 | ||
Parallel evolution and local differentiation in quinolone resistance in Pseudomonas aeruginosa | Q37835568 | ||
Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. | Q38626934 | ||
Bacterial resistance to the quinolone antimicrobial agents | Q38746710 | ||
Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones | Q39469894 | ||
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa | Q39470847 | ||
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients | Q39473195 | ||
Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). | Q39477717 | ||
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin | Q39698735 | ||
Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. | Q39785139 | ||
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli | Q39816339 | ||
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa | Q39816347 | ||
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. | Q40334912 | ||
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli | Q41788804 | ||
The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa | Q43184919 | ||
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients | Q44067245 | ||
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact | Q44132698 | ||
Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa | Q44426754 | ||
Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains | Q44786412 | ||
Contribution of ParE mutation and efflux to ciprofloxacin resistance in Pseudomonas aeruginosa clinical isolates | Q46172031 | ||
Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa | Q46397999 | ||
Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates | Q46412289 | ||
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gram-negative, plant-associated bacteria. | Q47887383 | ||
Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. | Q54105307 | ||
Contributions of efflux pumps to high level resistance of Pseudomonas aeruginosa to ciprofloxacin | Q79664046 | ||
Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping | Q80643394 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
P304 | page(s) | 1361-1368 | |
P577 | publication date | 2012-12-28 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance | |
P478 | volume | 57 |
Q64914064 | Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair M. smegmatis Growth and Disturb Chromosome Replication. |
Q59126430 | Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa |
Q57060635 | BACTOME-a reference database to explore the sequence- and gene expression-variation landscape of Pseudomonas aeruginosa clinical isolates |
Q40108765 | Biofilm formation and antibiotic susceptibility in dispersed cells versus planktonic cells from clinical, industry and environmental origins. |
Q98215924 | Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa |
Q98245614 | Efflux pump activity potentiates the evolution of antibiotic resistance across S. aureus isolates |
Q34992258 | Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon |
Q37712123 | Evolution and Epidemiology of Multidrug-Resistant Klebsiella pneumoniae in the United Kingdom and Ireland |
Q41066625 | Evolution of Cost-Free Resistance under Fluctuating Drug Selection in Pseudomonas aeruginosa |
Q40056971 | Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain. |
Q36262179 | High-throughput automated microfluidic sample preparation for accurate microbial genomics. |
Q38856197 | Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections |
Q38977280 | In Vitro Antibiofilm Efficacies of Different Antibiotic Combinations with Zinc Sulfate against Pseudomonas aeruginosa Recovered from Hospitalized Patients with Urinary Tract Infection |
Q41060499 | In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure. |
Q90472440 | Long-term Persistence of an Extensively Drug Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center |
Q64100644 | MexXY Multidrug Efflux System Is More Frequently Overexpressed in Ciprofloxacin Resistant French Clinical Isolates Compared to Hospital Environment Ones |
Q40559371 | Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients |
Q64238157 | Mutations in play an important role in ciprofloxacin-resistant |
Q61449168 | Persistence and Microevolution of in the Cystic Fibrosis Lung: A Single-Patient Longitudinal Genomic Study |
Q89671585 | Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics |
Q92429989 | Regulatory Mechanisms of the LuxS/AI-2 System and Bacterial Resistance |
Q41687386 | Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor |
Q52313185 | The Versatile Mutational Resistome of Pseudomonas aeruginosa. |
Q35482558 | The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria |
Q42659717 | The genetic basis of the fitness costs of antimicrobial resistance: a meta-analysis approach |
Q34922676 | The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility |
Q37120056 | Transcriptome Profiling of Antimicrobial Resistance in Pseudomonas aeruginosa |
Q61444724 | Virulence Characteristics and an Action Mode of Antibiotic Resistance in Multidrug-Resistant Pseudomonas aeruginosa |
Q35062974 | Whole genome and transcriptome analyses of environmental antibiotic sensitive and multi-resistant Pseudomonas aeruginosa isolates exposed to waste water and tap water. |
Q62899027 | Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre |
Q36300937 | Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis |
Search more.